Does the media prefer TLSI or AVR?

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 4 articles in the media. Anteris Technologies Global's average media sentiment score of 0.79 beat TriSalus Life Sciences' score of 0.47 indicating that Anteris Technologies Global is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anteris Technologies Global 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DRTS or TLSI?

In the previous week, Alpha Tau Medical had 5 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 9 mentions for Alpha Tau Medical and 4 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.47 beat Alpha Tau Medical's score of 0.18 indicating that TriSalus Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Tau Medical 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TriSalus Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TLSI or INMD?

In the previous week, InMode had 4 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 8 mentions for InMode and 4 mentions for TriSalus Life Sciences. InMode's average media sentiment score of 0.59 beat TriSalus Life Sciences' score of 0.47 indicating that InMode is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InMode 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TLSI or BVS?

In the previous week, TriSalus Life Sciences had 2 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for TriSalus Life Sciences and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.96 beat TriSalus Life Sciences' score of 0.47 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TriSalus Life Sciences (TLSI) Competitors

$4.73 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$4.79 +0.06 (+1.35%)

As of 06/26/2026 06:28 PM Eastern

Compare

TLSI vs. AVR, DRTS, INMD, BVS, and SIBN

Should you buy TriSalus Life Sciences stock or one of its competitors? MarketBeat compares TriSalus Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TriSalus Life Sciences include Anteris Technologies Global (AVR), Alpha Tau Medical (DRTS), InMode (INMD), Bioventus (BVS), and SiBone (SIBN). These companies are all part of the "medical equipment" industry.

How does TriSalus Life Sciences compare to Anteris Technologies Global?

TriSalus Life Sciences (NASDAQ:TLSI) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

2.6% of TriSalus Life Sciences shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

TriSalus Life Sciences has a net margin of -60.85% compared to Anteris Technologies Global's net margin of -5,148.78%. TriSalus Life Sciences' return on equity of 0.00% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%

TriSalus Life Sciences has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.43	-$39.23M	-$1.41	N/A
Anteris Technologies Global	$1.91M	492.51	-$94.14M	-$2.23	N/A

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 4 articles in the media. Anteris Technologies Global's average media sentiment score of 0.79 beat TriSalus Life Sciences' score of 0.47 indicating that Anteris Technologies Global is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anteris Technologies Global	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TriSalus Life Sciences has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

TriSalus Life Sciences presently has a consensus target price of $7.50, indicating a potential upside of 58.56%. Anteris Technologies Global has a consensus target price of $16.00, indicating a potential upside of 65.56%. Given Anteris Technologies Global's stronger consensus rating and higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

TriSalus Life Sciences beats Anteris Technologies Global on 9 of the 15 factors compared between the two stocks.

How does TriSalus Life Sciences compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Alpha Tau Medical has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-73.23%	-52.90%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

In the previous week, Alpha Tau Medical had 5 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 9 mentions for Alpha Tau Medical and 4 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.47 beat Alpha Tau Medical's score of 0.18 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TriSalus Life Sciences has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A
TriSalus Life Sciences	$45.15M	6.43	-$39.23M	-$1.41	N/A

Alpha Tau Medical presently has a consensus price target of $12.60, suggesting a potential upside of 15.81%. TriSalus Life Sciences has a consensus price target of $7.50, suggesting a potential upside of 58.56%. Given TriSalus Life Sciences' higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Alpha Tau Medical has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Alpha Tau Medical beats TriSalus Life Sciences on 9 of the 15 factors compared between the two stocks.

How does TriSalus Life Sciences compare to InMode?

TriSalus Life Sciences (NASDAQ:TLSI) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

InMode has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.43	-$39.23M	-$1.41	N/A
InMode	$370.49M	2.27	$93.83M	$1.36	10.75

In the previous week, InMode had 4 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 8 mentions for InMode and 4 mentions for TriSalus Life Sciences. InMode's average media sentiment score of 0.59 beat TriSalus Life Sciences' score of 0.47 indicating that InMode is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMode	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

InMode has a net margin of 23.27% compared to TriSalus Life Sciences' net margin of -60.85%. InMode's return on equity of 13.47% beat TriSalus Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
InMode	23.27%	13.47%	11.95%

TriSalus Life Sciences presently has a consensus price target of $7.50, suggesting a potential upside of 58.56%. InMode has a consensus price target of $16.00, suggesting a potential upside of 9.39%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TriSalus Life Sciences has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, InMode has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

Summary

InMode beats TriSalus Life Sciences on 11 of the 16 factors compared between the two stocks.

How does TriSalus Life Sciences compare to Bioventus?

TriSalus Life Sciences (NASDAQ:TLSI) and Bioventus (NASDAQ:BVS) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bioventus has a net margin of 4.94% compared to TriSalus Life Sciences' net margin of -60.85%. Bioventus' return on equity of 29.97% beat TriSalus Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
Bioventus	4.94%	29.97%	9.52%

Bioventus has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.43	-$39.23M	-$1.41	N/A
Bioventus	$576.30M	1.42	$22.73M	$0.41	23.85

TriSalus Life Sciences has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Bioventus has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

In the previous week, TriSalus Life Sciences had 2 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for TriSalus Life Sciences and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.96 beat TriSalus Life Sciences' score of 0.47 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TriSalus Life Sciences currently has a consensus price target of $7.50, suggesting a potential upside of 58.56%. Bioventus has a consensus price target of $14.20, suggesting a potential upside of 45.19%. Given TriSalus Life Sciences' higher probable upside, equities research analysts plainly believe TriSalus Life Sciences is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Bioventus beats TriSalus Life Sciences on 14 of the 17 factors compared between the two stocks.

How does TriSalus Life Sciences compare to SiBone?

TriSalus Life Sciences (NASDAQ:TLSI) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

In the previous week, TriSalus Life Sciences had 3 more articles in the media than SiBone. MarketBeat recorded 4 mentions for TriSalus Life Sciences and 1 mentions for SiBone. SiBone's average media sentiment score of 1.87 beat TriSalus Life Sciences' score of 0.47 indicating that SiBone is being referred to more favorably in the news media.

Company	Overall Sentiment
TriSalus Life Sciences	Neutral
SiBone	Very Positive

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 3.9% of SiBone shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

SiBone has higher revenue and earnings than TriSalus Life Sciences. SiBone is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.43	-$39.23M	-$1.41	N/A
SiBone	$200.93M	3.83	-$18.90M	-$0.39	N/A

TriSalus Life Sciences currently has a consensus target price of $7.50, indicating a potential upside of 58.56%. SiBone has a consensus target price of $23.00, indicating a potential upside of 32.72%. Given TriSalus Life Sciences' higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

TriSalus Life Sciences has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, SiBone has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

SiBone has a net margin of -8.10% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
SiBone	-8.10%	-9.56%	-7.06%

Summary

SiBone beats TriSalus Life Sciences on 10 of the 16 factors compared between the two stocks.

Get TriSalus Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLSI vs. The Competition

Export

Metric	TriSalus Life Sciences	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.52M	$8.46B	$6.83B	$12.17B
Dividend Yield	N/A	2.48%	2.66%	6.11%
P/E Ratio	-3.35	16.18	25.91	24.17
Price / Sales	6.43	6.67	548.81	101.11
Price / Cash	N/A	18.07	29.09	36.93
Price / Book	-6.96	3.37	10.82	6.38
Net Income	-$39.23M	$226.25M	$3.58B	$337.00M
7 Day Performance	12.62%	2.11%	1.90%	-0.23%
1 Month Performance	38.71%	-3.20%	-0.26%	-1.40%
1 Year Performance	-11.09%	0.80%	34.40%	27.76%

TriSalus Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLSI TriSalus Life Sciences	3.639 of 5 stars	$4.73 flat	$7.50 +58.6%	-11.1%	$290.52M	$45.15M	N/A	106	High Trading Volume
AVR Anteris Technologies Global	3.1645 of 5 stars	$10.15 -1.2%	$16.00 +57.6%	+138.0%	$986.35M	$1.91M	N/A	138	Gap Down
DRTS Alpha Tau Medical	2.9628 of 5 stars	$9.92 +1.2%	$12.60 +27.0%	+265.1%	$898.83M	N/A	N/A	80	Insider Trade Gap Down
INMD InMode	1.5671 of 5 stars	$14.76 +10.5%	$16.00 +8.4%	+3.1%	$848.71M	$374.64M	10.86	480	High Trading Volume
BVS Bioventus	4.1717 of 5 stars	$9.63 +3.6%	$14.20 +47.5%	N/A	$805.33M	$568.09M	23.51	1,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLSI) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TriSalus Life Sciences (TLSI) Competitors

TLSI vs. AVR, DRTS, INMD, BVS, and SIBN

How does TriSalus Life Sciences compare to Anteris Technologies Global?

Summary

How does TriSalus Life Sciences compare to Alpha Tau Medical?

Summary

How does TriSalus Life Sciences compare to InMode?

Summary

How does TriSalus Life Sciences compare to Bioventus?

Summary

How does TriSalus Life Sciences compare to SiBone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI vs. The Competition

TriSalus Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TriSalus Life Sciences (TLSI) Competitors

TLSI vs. AVR, DRTS, INMD, BVS, and SIBN

How does TriSalus Life Sciences compare to Anteris Technologies Global?

Do insiders & institutionals believe in TLSI or AVR?

Is TLSI or AVR more profitable?

Which has better earnings & valuation, TLSI or AVR?

Does the media prefer TLSI or AVR?

Which has more volatility and risk, TLSI or AVR?

Do analysts prefer TLSI or AVR?

Summary

How does TriSalus Life Sciences compare to Alpha Tau Medical?

Is DRTS or TLSI more profitable?

Does the media favor DRTS or TLSI?

Which has stronger earnings and valuation, DRTS or TLSI?

Do analysts recommend DRTS or TLSI?

Which has more volatility and risk, DRTS or TLSI?

Do institutionals & insiders hold more shares of DRTS or TLSI?

Summary

How does TriSalus Life Sciences compare to InMode?

Which has stronger earnings & valuation, TLSI or INMD?

Does the media refer more to TLSI or INMD?

Do insiders and institutionals have more ownership in TLSI or INMD?

Is TLSI or INMD more profitable?

Do analysts rate TLSI or INMD?

Which has more volatility and risk, TLSI or INMD?

Summary

How does TriSalus Life Sciences compare to Bioventus?

Do insiders and institutionals have more ownership in TLSI or BVS?

Is TLSI or BVS more profitable?

Which has preferable valuation & earnings, TLSI or BVS?

Which has more risk & volatility, TLSI or BVS?

Does the media favor TLSI or BVS?

Do analysts rate TLSI or BVS?

Summary

How does TriSalus Life Sciences compare to SiBone?

Does the media prefer TLSI or SIBN?

Do institutionals and insiders believe in TLSI or SIBN?

Which has stronger earnings & valuation, TLSI or SIBN?

Do analysts prefer TLSI or SIBN?

Which has more volatility & risk, TLSI or SIBN?

Is TLSI or SIBN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI vs. The Competition

TriSalus Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools